| abstract |
The present invention relates to novel hepatitis C virus (<HCV <) protease inhibitors, to pharmaceutical compositions containing one or more of these inhibitors, to methods of making such inhibitors, and to methods of using inhibitors for treating hepatitis C and the like. In particular, the present invention provides novel macrocyclic compounds which are protease inhibitors according to HCV NS3 / NS4a. In a most important embodiment, the present invention relates to macrocyclic compounds of the general formula, their stereoisomers, diastereomers, rotamers, pharmaceutically acceptable salts and solvates thereof. SHE |